Consort Partners’ Post

New review article out on the challenges associated with using #extracellularvesicles as #biomarkers in #neurodegenerative disease. Enjoy! https://lnkd.in/etyfDQEh

Good information about neurodegenerative diseases.

🤗 📝 We are happy to share this article from a group of French autoinflammatory experts, including representatives of the Tenon Hospital (RITA member since 2022). It describes the first dominant somatic mutation of MEFV p.Thr577Ala, responsible for a pyrin-associated autoinflammatory disease. Have a read! ⬇

Xtalks recently talked to us about Treg therapy for diseases like #ALS, #FTD and others. Listen to the full discussion here to learn more about our lead candidates and their potential to treat #neurodegenerative diseases. https://lnkd.in/e_5c3fRe #ENDFTD #Coyatherapeutics $Coya

🤗 📝 We are happy to share this article from a group of French autoinflammatory experts, including representatives of the Tenon Hospital (RITA member since 2022). It describes the first dominant somatic mutation of MEFV p.Thr577Ala, responsible for a pyrin-associated autoinflammatory disease. Have a read! ⬇ https://lnkd.in/dedcMnND

February is Rare Liver Diseases Month, and we want to highlight one of the greatest challenges for people living with a rare #liver disease — the long journey to a diagnosis. On average, it can take about 4-5 years for a person with a rare disease to receive an accurate diagnosis. For some people it can take more than a decade, and for many, their disease is never diagnosed at all. Alpha-1 antitrypsin deficiency (AATD) is an often-undiagnosed genetic condition that can lead to liver disease in children and adults. Significant unmet need exists for AATD-associated liver disease as a liver transplant is currently the only available treatment option, but is only applicable for patients who progress to end-stage liver disease. Hear from Lorrinda Gray-Davis, who shares the challenges she faced for over a decade*, before being diagnosed with AATD-associated liver disease. View her story here: https://lnkd.in/dGdS3nRz *Individual experiences may vary.

Multiple Sclerosis, or MS, impacts millions of people worldwide as one of the most common neurological diseases. Though there is no cure for the disease, scientists are beginning to unravel one of MS’ potential causes: Epstein-Barr Virus, or EBV, a typically symptomless virus latent in more than 90% of the population that has been implicated in a variety of diseases. Read about how Wistar’s resident EBV experts Drs. Paul Lieberman and Italo Tempera are investigating the links between EBV and MS that could be a first step in preventing the development of MS in certain cases: https://lnkd.in/eTc2n2-Z - Want to know more about Wistar research? Sign up for our newsletter here: https://bit.ly/3UInm0g #MSAwarenessWeek #multiplesclerosis #epsteinbarr #research

3 step cure for autoimmune disease? Great vision and overview from Robert Plenge. Step 1 - control inflammation Step 2 - reset the immune system (with CAR-Ts) Step 3 - promote homeostasis & repair https://lnkd.in/ejbNuUtN The article references some really strong data from 2022 where CAR-Ts were used in Systemic Lupus Erythematosus (SLE) to reset the immune system. It was a small study, but 5 of 5 patients were in remission, which persisted for 12 months. https://lnkd.in/eVRXAcHZ In 2024, this was followed up in "severe SLE (8 patients), idiopathic inflammatory myositis (3 patients), [and] systemic sclerosis (4 patients)" which showed similar very strong results. https://lnkd.in/e8kQDGft Very exciting times for the field!

Glis2 is an early effector of polycystin signaling and a target for therapy in polycystic kidney disease https://lnkd.in/ey6kV6Kg

Is your inflammatory bowel disease (IBD) research limited by conventional models that do not adequately translate to human response? Read our application note to learn how the Emulate Colon Intestine-Chip can be used to create more human-relevant models of immune-cell-driven IBD progression: https://bit.ly/44OghOL